Gene · 81607
Papers1,879
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
81 to 100 of 1,879
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| When more target antigen expression is less. | Cancer Cell | 2026 | 42208541 | PubTator, text mining | PubMed |
| Antibody-Drug Conjugates Beyond HER2 in Non-Small Cell Lung Cancer (NSCLC): Mechanisms, Emerging Targets, and Future Directions. | Biomolecules | 2026 | 42194027 | PubTator, text mining | PubMed |
| Nectin-4 immunohistochemistry distinguishes urothelial carcinoma in situ from reactive urothelium. | Virchows Arch | 2026 | 42159716 | PubTator, text mining | PubMed |
| SOX2-positive upper tract urothelial carcinoma: Clinicopathological characteristics and therapeutic implications. | Oncol Lett | 2026 | 42137465 | PubTator, text mining | PubMed |
| Nectin4-targeted molecular imaging for precise endoscopic diagnosis and image-guided surgery in bladder cancer. | Cell Rep Med | 2026 | 42127904 | PubTator, text mining | PubMed |
| A Spatial Atlas of Muscle-Invasive Bladder Cancer Reveals Lineage-Specific Vulnerabilities and Immune Architecture. | Cancer Discov | 2026 | 42126225 | PubTator, text mining | PubMed |
| Research progress of antibody-drug conjugates in the treatment of endometrial cancer. | Front Oncol | 2026 | 42125712 | PubTator, text mining | PubMed |
| Emerging biomarkers in IgA nephropathy, membranous nephropathy, and lupus nephritis. | Clin Chim Acta | 2026 | 42107815 | PubTator, text mining | PubMed |
| Enfortumab Vedotin plus Pembrolizumab as First-line Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Results from EV-202 Cohort 9. | Clin Cancer Res | 2026 | 42084607 | PubTator, text mining | PubMed |
| Evaluation of Tissue from Patients with Prostate Cancer Identifies B7-H3 as an Androgen-Regulated, Broadly Expressed, Combinatorial Therapeutic Target. | Clin Cancer Res | 2026 | 42053993 | PubTator, text mining | PubMed |
| Subacute Sclerosing Panencephalitis: How Measles Virus Adapts to the Brain. | Annu Rev Virol | 2026 | 42048564 | PubTator, text mining | PubMed |
| Cutaneous adverse reactions associated with enfortumab vedotin: a pharmacovigilance study based on the FDA adverse event reporting system. | Front Med (Lausanne) | 2026 | 42040559 | PubTator, text mining | PubMed |
| Bioinformatics profiling of NECTIN4 in lung cancer and comparative evaluation of NECTIN4-targeted ⁶⁸Ga-N188 and ¹⁸F-FDG PET/CT. | J Transl Med | 2026 | 42036686 | PubTator, text mining | PubMed |
| CDNFE suggests FNDC3B and NECTIN4 as drivers of precancer progression via PI3K/AKT EMT. | NPJ Precis Oncol | 2026 | 42032137 | PubTator, text mining | PubMed |
| B7-H3 Gene Expression Shapes Prognosis and Therapeutic Opportunities across Patient Groups with Prostate Cancer. | Clin Cancer Res | 2026 | 42012455 | PubTator, text mining | PubMed |
| ENVELOPE: enfortumab vedotin in patients with advanced small bowel adenocarcinoma refractory or intolerant to platinum-based therapy-phase II investigator-initiated trial (NCCH2412/MK015). | ESMO Gastrointest Oncol | 2026 | 42004625 | PubTator, text mining | PubMed |
Concordance and prognostic value of antibody drug conjugate and checkpoint inhibition targets in matched bladder cancer specimens from transurethral resection of the bladder, radical cystectomy and lymphadenectomy. | Urol Oncol | 2026 | 41986174 | PubTator, text mining | PubMed |
| Structure-Guided Engineering of TIGIT to Modulate Its Interaction With Nectin-4, a Tumour-Specific Antigen for the Development of Therapeutic Strategy. | Eur J Immunol | 2026 | 41928599 | PubTator, text mining | PubMed |
| Recent advances in immunotherapy for bladder cancer: mechanisms, clinical applications, and future perspectives. | Front Oncol | 2026 | 41919257 | PubTator, text mining | PubMed |
| Preliminary biological evaluation of a [177Lu]Lu-labeled peptide targeting Nectin-4. | EJNMMI Radiopharm Chem | 2026 | 41910915 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/81607/papers?page=5